Arrow Electronics (ARW) Margin Compression Reinforces Value Narrative Despite Low P/E

Arrow Electronics (ARW) recorded net profit margins of 1.6%, just below last year’s 1.7%, highlighting continued pressure on profitability. Over the past five years, earnings have declined by 10.2% per year. While forecasts call for 1.7% annual earnings growth and 4.7% revenue growth going forward, both metrics are expected to trail the wider US market. These numbers present a mixed picture for investors, with persistent declines in profit offset by the prospect of steady, if modest, growth.

See our full analysis for Arrow Electronics.

Next, we will see how these numbers compare to the broader narratives investors follow, highlighting where expectations meet reality and where surprises might challenge the consensus.

See what the community is saying about Arrow Electronics

NYSE:ARW Earnings & Revenue History as at Oct 2025
NYSE:ARW Earnings & Revenue History as at Oct 2025
Advertisement

Margin Stability Amidst Sector Shifts

  • Arrow's profit margins are projected to rise from the current 1.6% to 2.1% by 2028, reflecting analyst expectations for gradual improvement despite industry competition and cost pressures.
  • According to the analysts' consensus, margin gains are closely tied to a mix of efficiency initiatives and a shift toward higher-margin, recurring revenue streams.
    • Consensus narrative notes that value-added services and the adoption of cloud and software offerings are key drivers. These are expected to bolster margin resilience even as the customer base and market dynamics evolve.
    • However, consensus cautions that global uncertainties and supply chain pressures could still challenge margin progress. This demands continued focus on operational discipline.
  • Eager to see whether Arrow's push for higher margins can outpace emerging risks? Dive into the full consensus narrative for deeper insights. 📊 Read the full Arrow Electronics Consensus Narrative.

P/E Discount versus Industry Peers

  • Arrow's price-to-earnings ratio stands at 12.1x, significantly below the US electronics industry average of 25x and the peer average of 19x. This positions its shares as comparatively undervalued.
  • The analysts' consensus narrative highlights that this lower P/E may reflect investor caution around Arrow's profitability trends, but also leaves room for upside if the company delivers on long-term earnings growth.
    • Consensus notes that continued traction in recurring software revenues and improved margin stability could help close the valuation gap, especially if earnings forecasts are met or exceeded.
    • Consensus also points out that in the event of weaker profit recovery or sustained margin headwinds, the current discount could persist or deepen. This emphasizes the importance of execution on efficiency measures.

Profit Trends Outpace Share Reduction

  • Analysts expect Arrow's shares outstanding to decrease by 2.07% per year over the next three years, a trend that can amplify earnings per share growth if net income stabilizes or rises.
  • Based on the consensus narrative, analysts agree that while buybacks and stable share counts improve per-share metrics, the core challenge remains reversing a historic 10.2% annual earnings decline, which has overshadowed the benefit of fewer shares.
    • Consensus flags that even as operational improvements unlock some upside, sustainability depends on sector recovery and Arrow's ability to diversify beyond distribution, particularly into software and value-added services.
    • Consensus underscores that the ultimate impact of these trends hinges on Arrow’s ability to capture margin expansion without getting caught by ongoing customer and supply chain shifts.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Arrow Electronics on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Viewing the data from a different angle? Consider shaping your perspective into a narrative of your own in just a few minutes. Do it your way

A great starting point for your Arrow Electronics research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.

See What Else Is Out There

Arrow’s declining earnings and only modest growth outlook leave investors facing uncertainty about sustained profitability and sector outperformance.

If you’re seeking steadier performers, use stable growth stocks screener (2101 results) to find companies that consistently expand revenue and earnings regardless of shifting industry conditions.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

About NYSE:ARW

Arrow Electronics

Arrow Electronics, Inc. sources and engineers technology for manufacturers, service providers, and users of enterprise computing solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.

Excellent balance sheet with proven track record.

Advertisement

Weekly Picks

LO
Lou_Basenese
OPTH logo
Lou_Basenese on Optimi Health ·

The Only Psychedelic Company Already Selling MDMA and Psilocybin to Real Patients, Yet Priced Like It Doesn’t Exist

Fair Value:US$1155.3% undervalued
50 users have followed this narrative
2 users have commented on this narrative
9 users have liked this narrative
WE
WealthAP
NOVO B logo
WealthAP on Novo Nordisk ·

Novo Nordisk (NVO): Is the "Easy Growth" Story Over?

Fair Value:DKK 407.7719.9% undervalued
69 users have followed this narrative
0 users have commented on this narrative
8 users have liked this narrative
VA
ValueInvestingSubstack
ZTS logo
ValueInvestingSubstack on Zoetis ·

Zoetis down -50% over the past year

Fair Value:US$92.9217.2% undervalued
23 users have followed this narrative
0 users have commented on this narrative
9 users have liked this narrative
CE
CentryResearch
LEU logo
CentryResearch on Centrus Energy ·

Centrus Energy: The Next Nuclear Bottleneck Isn't Reactors. It's Fuel.

Fair Value:US$1907.4% undervalued
24 users have followed this narrative
0 users have commented on this narrative
11 users have liked this narrative

Updated Narratives

BR
Brunhilde_Wagner
CPRT logo
Brunhilde_Wagner on Copart ·

Compounder to Cash Generator in Real Time

Fair Value:US$2710.3% overvalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
WI
WisetoWealth
PYPL logo
WisetoWealth on PayPal Holdings ·

The Underrated Transformation of a Digital Payments Giant

Fair Value:US$90.3137.9% undervalued
6 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
BL
Blagget
TERA logo
Blagget on Terra Balcanica Resources ·

The C$4M Explorer Positioned to Become Europe's First Antimony Mine

Fair Value:CA$0.487.5% undervalued
3 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

CU
MSFT logo
CubanEros on Microsoft ·

A wonderful business at reasonable price.

Fair Value:US$419.917.3% undervalued
85 users have followed this narrative
0 users have commented on this narrative
6 users have liked this narrative
OS
oscargarcia
NVDA logo
oscargarcia on NVIDIA ·

The company that went from selling GPUs to gamers to becoming the AI arms dealer of the 21st century.

Fair Value:US$28029.8% undervalued
193 users have followed this narrative
9 users have commented on this narrative
15 users have liked this narrative
BE
PYPL logo
benjamin_lvieq on PayPal Holdings ·

PayPal: PayPal Doesn't Need to Grow – It Needs to Stop Falling – A Mispriced Cash Machine With a Cannibal Buyback

Fair Value:US$6513.7% undervalued
72 users have followed this narrative
2 users have commented on this narrative
11 users have liked this narrative

Trending Discussion

DE
TDOC logo
derek_3wsdg on Teladoc Health ·

You’ve overlooked the activist investor factor. Travis Cocke’s Voss has announced 5% ownership through a 13G filing. They’ve added to that 5% since, and in doing so, have created a structural trap door for 27.42 Million Shares actively sold short. Chuck will announce lots of positives on July 29 but it’s what Voss announces shortly after that will rock the overextended Teledoc shorts. The Walmart partnership is the tip of the iceberg. The market is missing the sheer regulatory and enterprise friction of modern corporate healthcare. Teladoc isn't a "consumer app"; it is the primary digital infrastructure integrated directly into the legacy backends of Tier-1 insurance companies and fortune 500 employers, covering 105 million+ lives. Teladoc is acting as the digital top-of-funnel engine for the world's largest retailer. If Voss pushes the narrative that Teladoc is effectively the outsourced digital brain of Walmart's entire healthcare footprint, the fair value shifts from a basic health multiple to an enterprise distribution premium. Additionally , we are in a structural gold rush for high-quality, legally compliant, longitudinal medical data to train vertical healthcare AI models. Large technology hyperscalers and pharmaceutical giants cannot simply scrape the internet for this; they need structured clinical inputs. Teladoc sits on one of the largest de-identified virtual medical datasets on earth. From the activist playbook , we’ll see Voss demand the immediate creation of a Data & Diagnostics Licensing Division, transforming a legacy liability into an incredibly high-margin, pure-software data asset that requires zero human clinician hours to scale. Chuck is doing great work and deserves credi5 for the Teledoc turnaround but it will be Travis Cocke who will be responsible for a share price way beyond your $15 valuation.

1
|
0
AN
CSMG3 logo
andre_k1tsg on Companhia de Saneamento de Minas Gerais ·

Gostei

0
|
0